News
(2)April 2026
Absci details clinical strategy and AI platform for novel therapeutics
# 📰 What This Document Is 📖 This document is an Annual Report on Form 10-K, which is one of the most comprehensive reports a public company files with the SEC. Think of it as a massive, deep dive into the company's entire year—its finances, its risks, its management's plans, and its history. Bec
Absci advances AI biologics, targeting A.A. and Endometriosis milestones
# 🗳️ What This Document Is This document is a Definitive Proxy Statement (DEF 14A) for Absci Corp’s 2026 Annual Meeting of Stockholders. Simply put, this is a massive, formal letter from the company to its shareholders that details not only the important operational updates (like new drug progress)
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.